The IMID Forum
Keeping you up to date with the latest and most important updates in immune-mediated inflammatory diseases.
Filtered episodes(8)
- StandardSummaries onlyAuthor Interview: Professor Valentino Paci, April 2026
Published Apr 30, 2026
Author InterviewJoin Professor Peter Nash from the Griffith University in Brisbane, and am Professor Valentino Paci, Medical researcher specialized in immune-mediated diseases, with a particular focus on spondyloarthritis. Collaboration and knowledge exchange are integral to his research philosophy, as they discuss his recent paper ‘Does Prior Exposure Affect Retention? A Real‑World, Multicentre Assessment of IL‑17 Inhibitor Cycling in Psoriatic Arthritis?’.
- StandardSummaries onlyAuthor Interview: Professor Helena Marzo-Ortega, March 2026
Published Apr 9, 2026
Author InterviewJoin Professor Peter Nash from the Griffith University in Brisbane, and Professor Helena Marzo-Ortega an academic clinician and the Clinical Lead of the multi-award winning Leeds Specialist Spondyloarthropathy service at The Leeds Teaching Hospitals NHS Trust, as they discuss her recent paper ‘EULAR points to consider and consensus definitions for difficult-to-manage and treatment-refractory psoriatic arthritis’.
- StandardSummaries onlyAuthor Interview: Doctor Carlo Tur, February 2026
Published Mar 12, 2026
Author InterviewJoin Professor Peter Nash from the Griffith University in Brisbane, and Doctor Carlo Tur, from the department of Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University, Erlangen-Nurnberg., as they discuss his recent paper ‘Effects of different B-cell-depleting strategies on the lymphatic tissue’.
- StandardSummaries onlyAuthor Interview: Professor Matthew Brown, 2026
Published Feb 3, 2026
Author InterviewJoin Professor Peter Nash from the Griffith University in Brisbane, and Professor Matthew Brown, the Chief Scientific Officer at Genomics England, as they discuss his recent paper ‘Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: Pooled results from Phase 2b/3 trials’.
- StandardSummaries onlyAuthor Interview: Professor Filip Rob, 2025
Published Nov 20, 2025
Author InterviewJoin Professor Peter Nash from the Griffith University in Brisbane, and Professor Filip Rob, the Department of head of the Dermatovenereology at the Second Faculty of Medicine, Charles University, University Hospital Bulovka, Prague, Czech Republic, as they discuss his recent paper ‘Efficacy, safety, and drug survival during the first year of biologic therapy for psoriasis in elderly versus younger patients’.
- StandardSummaries onlyAuthor Interview: Doctor David Kellner, September 2025
Published Oct 2, 2025
Author InterviewJoin Professor Peter Nash from the Griffith University in Brisbane, and Doctor David Kellner, an IGNITE-MSCR Fellow of the Division of Rheumatology, from UCLA Medical Centre, LA, USA, as they discuss his recent review ‘Effect of glucagon-like peptide 1 receptor agonists on patients with rheumatoid arthritis’.
- StandardSummaries onlyAuthor Interview: Doctor Rodrigo Garcia‑Salinas, August 2025
Published Aug 28, 2025
Author InterviewJoin Professor Peter Nash from Griffith University in Brisbane, and Dr Rodrigo Garcia‑Salinas from Hospital Italiano de La Plata in Argentina, as they discuss Dr Garcia-Salinas’ recent publication ‘Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns’.
- StandardSummaries onlyAuthor Interview: Doctor Martin Schaefer and Professor Anja Strangfeld, July 2025
Published Aug 14, 2025
Author InterviewJoin Professor Peter Nash from the Griffith University in Brisbane, and authors Dr Martin Schaefer from the German Rheumatology Research Center in Berlin, Germany and Professor Anja Strangfeld, the head of epidemiology at the German Rheumatology Research Centre. In this episode they discuss a recent study from the German RABBIT registry, investigating the comparative risk of malignancies in rheumatoid arthritis patients treated with JAK inhibitors versus bDMARDs.